- Home
- ACON vs APM Comparison
ACON vs APM Comparison
Compare ACON & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- APM
- Stock Information
- Founded
- ACON 2008
- APM 2010
- Country
- ACON United States
- APM United Kingdom
- Employees
- ACON N/A
- APM N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- APM Health Care
- Exchange
- ACON Nasdaq
- APM Nasdaq
- Market Cap
- ACON 4.8M
- APM 5.6M
- IPO Year
- ACON 2022
- APM 2018
- Fundamental
- Price
- ACON $7.64
- APM $0.99
- Analyst Decision
- ACON Buy
- APM
- Analyst Count
- ACON 2
- APM 0
- Target Price
- ACON $481.00
- APM N/A
- AVG Volume (30 Days)
- ACON 75.1K
- APM 138.3K
- Earning Date
- ACON 04-09-2025
- APM 05-06-2025
- Dividend Yield
- ACON N/A
- APM N/A
- EPS Growth
- ACON N/A
- APM N/A
- EPS
- ACON N/A
- APM 0.00
- Revenue
- ACON $45,724.00
- APM N/A
- Revenue This Year
- ACON $251.35
- APM $157,729.10
- Revenue Next Year
- ACON N/A
- APM N/A
- P/E Ratio
- ACON N/A
- APM $270.99
- Revenue Growth
- ACON N/A
- APM N/A
- 52 Week Low
- ACON $7.26
- APM $0.46
- 52 Week High
- ACON $6,241.05
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- ACON 33.40
- APM 51.54
- Support Level
- ACON $8.15
- APM $0.79
- Resistance Level
- ACON $8.30
- APM $0.97
- Average True Range (ATR)
- ACON 1.25
- APM 0.12
- MACD
- ACON 6.41
- APM 0.02
- Stochastic Oscillator
- ACON 6.94
- APM 33.74
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.